Management of Post-operative Nausea & Vomiting in Adults Using ERAS Protocols

A presentation for HealthTrust Members February 1, 2023



Ugene Sano, PharmD, PGY-1 Pharmacy Resident Cooperman Barnabas Medical Center Livingston, New Jersey Preceptor: Timothy Jacisin, PharmD, BCPS

Speaker Disclosures

- There are no financial interests to disclose for myself or the preceptor in the last 24 months.
- This presentation may include the mention of brand products or drugs. All content is for educational purposes only.
- Certain medications may not have an FDA-approved indication for their use in post-operative nausea & vomiting. These medications will be labeled with "off-label" under indications.

Objectives


For Pharmacists & Pharmacy Technicians

- Recall the definition of enhanced recovery after surgery (ERAS)
- Recognize medications used in the pharmacologic management of post-operative nausea and vomiting (PONV) and indications for use
- Identify evidence-based practice guidelines for the management of PONV

Post-operative nausea & vomiting (PONV)

- ~30% of all surgical patients experience PONV
 - ~80% of high-risk surgical patients
- Associated with poor patient outcomes
 - Longer stay in Post-Anesthesia Care Unit (PACU)
 - Higher incidence of hospital admission
 - Increased healthcare costs
 - Patient dissatisfaction
- Pathophysiology = multifactorial

Pathophysiology of nausea & vomiting



Source: Singh P, et al. Therapy Adv Gastroenterol. 2016;9(1):98-112.

Major receptors of nausea & vomiting

Serotonin (5-HT3) receptors	Substance P NK- 1 receptors	Dopamine D2/3 receptors
Acetylcholine receptors	Histamine-1 receptors	Opiate mu, kappa, and delta receptors


Source: Singh P, et al. Therapy Adv Gastroenterol. 2016;9(1):98-112.


Key: 5-HT: 5-hydroxytryptamine

NK: Neurokinin

Risk factor stratification

- Risk scores intended to predict incidence of PONV and guide choice in prophylactic management
- Each risk factor = 1 point
 - Risk factor corresponds to percentage risk of PONV
 - Score of 0 = 10%
 - 1 = 20%
 - 2 = 40%
 - 3 = 60%
 - 4 = 80%
- Additional risk factors: younger age, surgery type, opioid analgesia





Apfel Scoring		
Points	Scoring	
0 - 1	Low	
2	Moderate	
3 +	High	

Simplified Apfel Score

Guidance for choice of anti-emetic prophylaxis

Risk stratification	Management
Low-moderate risk (0-2 risk factors)	2 antiemetics
High risk (3+ factors)	3-4 antiemetics

- Additional strategies for risk mitigation
 - Minimize use of nitrous oxide, volatile anesthetics, high-dose neostigmine
 - Opioid sparing & multimodal approaches to analgesia
 - Regional anesthesia

Sources: Smith CA, et al. *J Perianesth Nurs*. 2016;31(2):158-71. Gan TJ, et al. *Anesth Analg*. 2020;131(3):411-48.

Pt case: Nida Santiago

- Nida is a 29-year-old female that is scheduled for a bariatric surgical procedure.
- Past medical history: Exercise-induced asthma
- Surgical history: None
- Social history: 1-2 glasses of wine on weekends, denies tobacco use or recreational substances
- Medications: Albuterol inhaler as needed, multivitamin

Assessment question: Based on this patient's Apfel score, how many prophylactic anti-emetics should be prescribed to Nida?

- A. 1
- B. 2
- C. 3
- D. 4
- E. O


Assessment question: Based on this patient's Apfel score, how many prophylactic anti-emetics should be prescribed to Nida?

- A. 1
- <mark>B. 2</mark>
- C. 3
- D. 4
- E. O

Enhanced Recovery After Surgery (ERAS)

- Set of interventions designed to help body mitigate and cope with stress of surgery
 - Accelerates recovery
 - Multi-modal & multi-disciplinary
- Benefits:
 - Reduces risk of postoperative complications
 - Reduces hospital length of stay & rates of readmissions
 - Reduces costs
 - Improves patient satisfaction

ERAS Elements



- management
- Carbohydrate • loading
- Nausea & vomiting prophylaxis
- Blood pressure • control
- Body temperature • control

- Multimodal approach of nausea & vomiting

Benefits of ERAS

Study	Study findings
Das-Neves-Pereira JC, et al. "Fast-track rehabilitation for lung cancer lobectomy: a five-year experience"	Reduction in post-operative complications (e.g. constipation after opioids use) Reduced hospital stay
Muehling BM, et al. "Reduction of postoperative pulmonary complications after lung surgery using a fast track clinical pathway"	Reduction in postoperative pulmonary complications

Assessment question: Which of the following is false regarding the definition of ERAS?

- A. A set of interventions designed to help body mitigate and cope with stress of surgery
- B. It provides the benefits of reduced length of hospital stay and reduction of post-operative complications
- C. It is a multi-modal, multi-disciplinary approach
- D. A set of interventions performed by nurses to only improve cost savings for surgical patients


Assessment question: Which of the following is false regarding the definition of ERAS?

- A. A set of interventions designed to help body mitigate and cope with stress of surgery
- B. It provides the benefits of reduced length of hospital stay and reduction of post-operative complications
- C. It is a multi-modal, multi-disciplinary approach

 D. A set of interventions performed by nurses to only improve cost savings for surgical patients

Anti-emetics by Pharmacologic Class

Overview of pharmacologic classes



5-HT3 Receptor antagonists

- <u>Mechanism of action</u>: Selectively blocks serotonin 3 (5-HT3) peripherally in the vagal nerve terminals and centrally in the chemoreceptor trigger zone
- <u>Medications</u>: Ondansetron, dolasetron, granisetron, palonosetron, ramosetron, tropisetron
- <u>Adverse effects</u>: QTc prolongation, risk of serotonin syndrome

Ondansetron

- Indications: PONV treatment & prevention
- Dosing:
 - Prevention:
 - Moderate-high risk: IV 4 mg once at end of surgery
 - Low-risk: May be considered, 4 mg
 - Treatment:
 - 4 mg once

- Half-life: 3-6 hours
- Onset of action: ~30 minutes
- Formulations: oral tablet, oral disintegrating tablet, IV
- Additional considerations:
 - No renal dose adjustments
 - QTc prolongation associated with doses of >16 mg/24 hours

Palonosetron

- Indications: PONV prevention
- **Dosing**: 0.075 mg IV once immediately prior to anesthesia induction
- Half-life: ~40 hrs
- Additional considerations:
 - No renal or hepatic dose adjustments

Granisetron

- Indications: Off-label for PONV treatment & prevention
- **Dosing**: 5 20 mcg/kg at end of surgery
 - 0.35 to 3 mg
- Formulations: IV, subcutaneous, oral
- Half-life:
 - IV: 5 9 hrs
- Onset of action: ~1-3 minutes
- Additional considerations:
 - Side effect: Constipation
 - CYP3A4 substrate
 - No renal adjustment for IV, PO

Sources: Aloxi[®] (palonosetron hydrochloride injection). Package insert. 2006. Sustol[®] (granisetron extended-release injection). Package insert. 2016.

NK-1 Receptor antagonists

- Mechanism of action: Inhibits the substance
 P/neurokinin 1 (NK-1) receptor to prevent acute and delayed vomiting
- <u>Medications</u>: aprepitant, fosaprepitant, rolapitant
- <u>Adverse effects:</u> Hypersensitivity reactions

Aprepitant

- Indications: PONV prevention
- **Dosing** : 40 mg PO once within 3 hours prior to anesthesia induction
- **Side effects**: fatigue, hypotension
- Half-life: ~ 9-13 hours
- Additional considerations:
 - CYP3A4 inhibitor
 - No renal dose adjustment
 - Caution in severe hepatic impairment

*****NOTE: Reduces efficacy of hormonal contraception** during treatment and for 1 month following last aprepitant dose

• Alternative/backup contraception should be taken during and after 1 month of treatment

Sources: Emend (aprepitant capsules). Package insert. 2010. Emend (fosaprepitant dimeglumine) for injection. Package insert. 2016.

Fosaprepitant

- Indications: Off-label use for PONV prevention
- **Dosing:** 150 mg IV once prior to anesthesia induction
- **Side effects**: fatigue, diarrhea, infusion site reaction
- Half-life: Once converted to aprepitant → ~9-13 hours

• Additional considerations:

- Prodrug of aprepitant
- No specified renal or hepatic adjustments
- CYP3A4 substrate → caution with concomitant use of inhibitors/inducers

Rolapitant

- Indications: Off-label use for PONV prevention
- **Dosing** : 70 200 mg PO preoperatively
- Side effects: Neutropenia, dizziness, hiccups, dyspepsia
- Half-life: ~ 7 days
- Additional considerations:
 - Contraindicated with concomitant use of CYP2D6 substrates with a narrow therapeutic index
 - No renal dose adjustment indicated not studied
 - Avoid use in patients with Child-Pugh class C

Glucocorticoids

- Mechanism of action: not well-established for antiemetic properties
- <u>Medications</u>: dexamethasone, methylprednisolone
- <u>Adverse effects</u>: psychiatric disturbances (e.g. confusion), hyperglycemia, immunosuppression, adrenal suppression

Dexamethasone

- Indications: Off-label for prevention of PONV
- **Dosing**: 4-10 mg IV once before or after induction of anesthesia
- Half-life: IV: ~1-5 hours
- Onset of action: IV rapid.
- Additional considerations:
 - Dose depends on risk and type of surgery
 - No renal or hepatic adjustment

Antihistamines

- <u>Mechanism of action</u>: Muscarinic-blocking effect for antiemetic effect
- <u>Medications</u>: Dimenhydrinate, promethazine, diphenhydramine
- <u>Adverse effects</u>: tachycardia, sedation, urinary retention, constipation, flushing, confusion, blurred vision, dry mouth
- <u>Warning</u>: Avoid use in older adults Beer's criteria medications.

Dimenhydrinate

- Indications: Off-label use for prevention of PONV
- **Dosage**: 50 mg once prior to procedure, then 50 mg postprocedure
- Formulations: PO, IV, IM
- Half-life:
 - IV: unknown
 - PO: ~5-8 hours
- **Onset of action**: immediate
- Additional considerations:
 - Avoid use in older adults.

Sources: Kothari SN, et al. Surg Endosc. 2000;14(10):926-9. Phenergan[®] (promethazine hydrochloride). Package insert.

Promethazine

- Indications: Off-label use for prevention & treatment of PONV
- Dosage:
 - **Prevention**: 6.25 mg PO/IV/IM once
 - Treatment: 12.5 25 mg PO or PR as needed every 4-6 hours
- Half-life: IV ~9-16 hours
- **Onset of action**: ~5 minutes
- Additional considerations:
 - To avoid intolerable adverse effects, recommended max dose of 50 mg/day
 - IV & IM are generally avoided due to risk of severe tissue injury
 - Avoid use in older adults.

Diphenhydramine

- Indications: Off-label use for treatment of PONV
- Dosage:
 - PO: 25 50 mg every 4-6 hours as needed
 - IV, IM: 10 50 mg every 6 hours as needed
- Formulations: PO, IV, IM
- Half-life: 7 12 hours
- Additional considerations:
 - Avoid use in older adults

Anticholinergics

- Mechanism of action: Inhibits anticholinergic receptors
- <u>Medicines</u>: scopolamine
- <u>Adverse effects</u>: tachycardia, sedation, urinary retention, constipation, flushing, confusion, blurred vision, dry mouth
- <u>Warning</u>: Avoid use in older adults Beer's criteria medications

Source: Transderm Scop[®] (scopolamine transdermal system patch). Package insert. 2013.

Scopolamine

- Indications: Prevention of PONV
- **Dosing**: 1 transdermal patch (1 mg/3 days) behind ear the night before surgical procedure
 - Remove 24 hours after procedure
 - May also be applied at least 1-2 hours prior to surgical procedure
- Half-life: 9.5 hours
- Onset of action: 4-8 hours
- Additional considerations:
 - Contraindicated in patients with narrow angle closure glaucoma
 - No renal or hepatic impairment adjustments

Dopamine antagonists/Antipsychotic agents

- Mechanism of Action: Antagonizes the dopamine 2 receptors in the chemoreceptor trigger zone, which results in inhibitory signaling
- Antipsychotic medications: droperidol, haloperidol, perphenazine
- General antidopaminergic medications: haloperidol, amisulpride
- Adverse effects: QTc prolongation, somnolence
- Contraindications: Parkinson's disease, dementia of Lewy bodies

Sources: Droperidol injection, solution. Package insert. 2019. *Haldol*[®] (haloperidol injection). Package insert. 2013.

Droperidol

- Indications: Prevention of PONV
- **Dosing**: 0.625-1.25 mg IV given at end of procedure
- Onset of action: 3-10 minutes
- Half-life: ~2 hours
- Additional considerations:
 - Black box warning: QTc prolongation and development of arrhythmias
 - Additional side effects: hypotension, tachycardia

Haloperidol

- Indications: Off-label use for PONV prevention for moderate to highrisk patients
- Dosing: 0.5 2 mg IV once after induction of anesthesia or at end of surgery
- Half-life: IV 14-26 hours
- Additional considerations:
 - Black box warning: Increased mortality in elderly patients with dementiarelated psychosis
 - Additional side effects: extrapyramidal reactions, parkinsonism

Perphenazine

- Indication: Off-label prevention of PONV
- Dosing: 5 mg IV
- Half-life: ~9-12 hours
- Additional considerations:
 - Black box warning: Increased mortality in elderly patients with dementiarelated psychosis
 - No renal dose adjustments specified use with caution
 - Contraindicated in patients with liver damage

Metoclopramide

- Indications: Off-label treatment of PONV
- Dosing: 10 mg once
- Formulations: PO, IV, IM
- Half-life:
 - IV: 1-3 minutes
 - IM: 10-15 minutes
 - PO: 30-60 minutes

• Additional considerations:

• Caution for CNS depression, extrapyramidal symptoms, hyperprolactinemia

Literature analysis of Amisulpride: Kranke P, et al.

Title	Amisulpride prevents post-operative nausea and vomiting in patients at high risk: a randomized, double-blinded, placebo-controlled trial
Objective	To assess the efficacy of amisulpride 5 mg IV in combination with standard of antiemetic to prevent PONV in adult surgical patients
Design	Double-blind, randomized, placebo-controlled, international, multi-center trial Included patients with Apfel scores of 3-4 N=1,147 \rightarrow 572 participants with intervention, 575 participants with placebo
Intervention	Amisulpride 5 mg IV once vs. placebo In combination with 1 non-dopaminergic antiemetic (ondansetron, dexamethasone)
Primary endpoint	Incidence of PONV prevented in 24 hours post-surgical procedure
Results	Complete response occurred in 57.7% of intervention group vs. 46.6% in placebo group (95% Cl 5.3-16.8%, p<0.001).
Conclusion	Amisulpride IV was safe and effective for PONV prophylaxis when given in combination with another antiemetic from another class.

Source: Kranke P, et al. Anesthesiology. 2018;128(6):1099-106.

Assessment question: Which of the following anti-emetics has actions by inhibiting serotonin?

- A. Rolapitant
- B. Perphenazine
- C. Palonosetron
- D. Dexamethasone

Assessment question: Which of the following anti-emetics has actions by inhibiting serotonin?

- A. Rolapitant
- B. Perphenazine
- C. Palonosetron
- D. Dexamethasone

Assessment Question: Which of the following medication classes would not be appropriate to provide to Nida as part of her PONV regimen?

- A. Anticholinergics
- B. Dopamine agonists
- C. Serotonin 3 inhibitors
- D. Corticosteroids

Assessment Question: Which of the following medication classes would not be appropriate to provide to Nida as part of her PONV regimen?

- A. Anticholinergics
- B. Dopamine agonists
- C. Serotonin 3 inhibitors
- D. Corticosteroids

Summary of anti-emetics

Pharmacologic class	Medications
5-HT3 Antagonists	Ondansetron Granisetron Palonosetron
NK-1 Receptor Antagonists	Aprepitant Fosaprepitant Rolaprepitant
Corticosteroids	Dexamethasone
Anticholinergics	Scopalamine
Antihistamines	Dimenhydrinate Diphenhydramine Promethazine
Antipsychotics	Droperidol Haloperidol Perphenazine
Dopamine antagonists	Amisulpride Metoclopramide

Combination therapy

- 2020 PONV guidelines in multimodal prophylaxis in patients with 1+ risk factors
- Examples of pharmacologic therapy combinations:
 - 5HT3 antagonists + dexamethasone
 - 5HT3 antagonists + aprepitant
 - Dexamethasone + aprepitant
 - 5HT3 antagonist + droperidol
 - Haloperidol + dexamethasone
 - Metoclopramide + dimenhydrinate
 - Aprepitant + dexamethasone + ondansetron

Pt case: Nida Santiago

- Nida is a 29-year-old female that is scheduled for a bariatric surgical procedure.
- Past medical history: Exercise-induced asthma
- Surgical history: None
- Social history: 1-2 glasses of wine on weekends, denies tobacco use or recreational substances
- Medications: Albuterol inhaler as needed, multivitamin

Assessment question: Based on the patient's Apfel score, which of the following would be appropriate for Nida as PONV prophylaxis?

- A. Metoclopramide + amisulpride
- B. Ondansetron
- C. Scopolamine + dimenhydramine
- D. Aprepitant + dexamethasone

Assessment question: Based on the patient's Apfel score, which of the following would be appropriate for Nida as PONV prophylaxis?

- A. Metoclopramide + amisulpride
- B. Ondansetron
- C. Scopolamine + dimenhydramine
- D. Aprepitant + dexamethasone

Assessment question: If Nida were to experience vomiting despite appropriate PONV prophylaxis, which of the following pharmacologic options would *not* be appropriate for treatment?

- A. Scopolamine
- B. Metoclopramide
- C. Ondansetron
- D. Haloperidol

Assessment question: If Nida were to experience vomiting despite appropriate PONV prophylaxis, which of the following pharmacologic options would *not* be appropriate for treatment?

- A. Scopolamine
- B. Metoclopramide
- C. Ondansetron
- D. Haloperidol

References

- Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Therap Adv Gastroenterol. 2016;9(1):98-112. doi: 10.1177/1756283X15618131.
- Smith CA, Ruth-Sahd L. Reducing the Incidence of Postoperative Nausea and Vomiting Begins With Risk Screening: An Evaluation of the Evidence. J Perianesth Nurs. 2016;31(2):158-71. doi: 10.1016/j.jopan.2015.03.011.
- Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA Surg. 2017;152(3):292-8. doi: 10.1001/jamasurg.2016.4952.
- Feldheiser A, Aziz O, Baldini G, Cox BP, Fearon KC, Feldman LS, et al. Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice. Acta Anaesthesiol Scand. 2016;60(3):289-334. doi: 10.1111/aas.12651.
- Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85-113. doi: 10.1213/ANE.0000000000002.
- Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2020;131(2):411-48. doi: 10.1213/ANE.000000000004833.
- Stenberg E, Dos Reis Falcão LF, O'Kane M, Liem R, Pournaras DJ, Salminen P, et al. Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update. World J Surg. 2022;46(4):729-51. doi: 10.1007/s00268-021-06394-9.
- Schwartz J, Gan TJ. Management of postoperative nausea and vomiting in the context of an Enhanced Recovery after Surgery program. Best Pract Res Clin Anaesthesiol. 2020;34(4):687-700. doi: 10.1016/j.bpa.2020.07.011.
- Rajan N, Joshi GP. Management of postoperative nausea and vomiting in adults: current controversies. Curr Opin Anaesthesiol. 2021;34(6):695-702. doi: 10.1097/ACO.000000000000001063.
- Smith CA, Ruth-Sahd L. Reducing the Incidence of Postoperative Nausea and Vomiting Begins With Risk Screening: An Evaluation of the Evidence. J Perianesth Nurs. 2016;31(2):158-71. doi: 10.1016/j.jopan.2015.03.011.
- Murakami C, Kakuta N, Kume K, et al. A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis. Biomed Res Int. 2017;2017:5703528. doi: 10.1155/2017/5703528.
- Brown JK, Singh K, Dumitru R, et al. The Benefits of Enhanced Recovery After Surgery Programs and Their Application in Cardiothoracic Surgery. Methodist Debakey Cardiovasc J. 2018;14(2):77-88. doi: 10.14797/mdcj-14-2-77.
- Das-Neves-Pereira JC, Bagan P, Coimbra-Israel AP, et al. Fast-track rehabilitation for lung cancer lobectomy: a five-year experience. Eur J Cardiothorac Surg. 2009;36(2):383-91; discussion 391-2. doi: 10.1016/j.ejcts.2009.02.020.
- Muehling BM, Halter GL, Schelzig H, et al. Reduction of postoperative pulmonary complications after lung surgery using a fast track clinical pathway. Eur J Cardiothorac Surg. 2008.; 34 1: 174–80.
- Kranke P, Bergese SD, Minkowitz HS, et al. Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial. Anesthesiology. 2018;128(6):1099-1106. doi: 10.1097/ALN.00000000002133.
- Kothari SN, Boyd WC, Bottcher ML, et al. Antiemetic efficacy of prophylactic dimenhydrinate (Dramamine) vs ondansetron (Zofran): a randomized, prospective trial inpatients undergoing laparoscopic cholecystectomy. Surg Endosc. 2000;14(10):926-9. doi: 10.1007/s004640080055.

Thank you!

Ugene Sano, PharmD, PGY-1 Pharmacy Resident UgeneGabrielle.Sano@rwjbh.org